RespireRx Pharmaceuticals, Inc. (RSPI)
| Market Cap | 2.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.74M |
| Shares Out | 25.86M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $0.0372 |
| Previous Close | $0.0379 |
| Change ($) | -0.0007 |
| Change (%) | -1.85% |
| Day's Open | 0.0370 |
| Day's Range | 0.0330 - 0.0450 |
| Day's Volume | 724,392 |
| 52-Week Range | 0.0200 - 0.2230 |
News
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the OTC...
About RSPI
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system's endogenous cannabinoid receptors for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, inc... [Read more...]
| Industry Biotechnology | Founded 1987 |
| Stock Exchange OTCMKTS | Ticker Symbol RSPI |